<DOC>
	<DOCNO>NCT02998450</DOCNO>
	<brief_summary>The purpose Phase 1a , first human , randomize , double-blind , placebo-controlled study evaluate safety , tolerability , PK PD profile orally administer IMR-687 healthy adult subject .</brief_summary>
	<brief_title>A Study IMR-687 Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Hemoglobin SC Disease</mesh_term>
	<criteria>Be healthy judge Investigator basis prestudy test perform Screening , healthy body mass index ( BMI ) , healthy body weight , laboratory result within normal laboratory reference range determine clinically significant Investigator ; free drug abuse . Females pregnant , try become pregnant , breastfeed ; male female partner try conceive . Asthmatics individual use may use albuterol rescue inhaler nebulizer . A significant history cardiovascular disease . On ECG , QTcF &gt; 450 m presence clinically significant abnormality determine Investigator . Elevated blood pressure . Use within 30 day prior Day 1 inhibitor substrates target IMR687 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Sickle Beta 0 Thalassemia</keyword>
</DOC>